



Figure S1: Correlation between VSIG4 expression and survival of HCC patients with HCV. (A) OS curves of HCC patients with HCV infection. (B) DFS curves of HCC patients with HCV infection. Log rank test, *P < 0.05, **P < 0.01.

Table S2: Cox regression analysis of VSIG4 and clinicopathological characteristics for OS and DFS of HCC patients with HBV.

Clinicopathological Characteristics		OS		DFS	
		HR (95% CI)	P value ^b	HR (95% CI)	P value
Age(years)	≤45 VS. >45	0.379 (0.074 - 1.940)	0.244	0.786 (0.227 - 2.714)	0.703
Gender	Male VS. Female	1.485 (0.587 - 3.756)	0.404	1.313 (0.543 - 3.172)	0.545
Child-Pugh	A VS. B/C	0.925 (0.251 - 3.107)	0.907	1.491 (0.539 - 4.120)	0.442
Cirrhosis	No VS. Yes	0.594 (0.205 - 1.718)	0.336	0.424 (0.182 - 0.988)	0.047*
AFP(ug/L)	≤400 VS. >400	0.256 (0.071 - 0.927)	0.038*	0.413 (0.117 - 1.457)	0.169
	T ₁ /T ₂ VS. T ₃ /T ₄	1.255 (0.461 - 3.417)	0.657	0.771 (0.311 - 1.910)	0.573
TNM stage	N ₀ VS. N ₁	1.014 (0.384 - 2.680)	0.977	1.022 (0.430 - 2.430)	0.961
	M ₀ VS. M ₁	3.259 (0.895 - 11.863)	0.073	0.929 (0.354 - 2.437)	0.881
Differentiation	High/Moderate VS. Low	0.552 (0.223 - 1.365)	0.199	0.524 (0.228 - 1.204)	0.128
VSIG4 Expression	Low VS. High ^a	5.129 (1.593 - 16.516)	0.006*	3.390 (1.271 - 9.042)	0.015*

Abbreviations: HR = hazard ratio; 95%CI = 95% confidence interval; AFP = alpha-fetoprotein.

a: The median expression level of VSIG4 was used as the cutoff. Low VSIG4 expression in each of the 32 patients was defined as a value below the 50th percentile. High VSIG4 expression in each of the 32 patients was defined as a value above the 50th percentile.

b: Cox regression, *P < 0.05, **P < 0.01.

Table S3: Relationship between the VSIG4 expression and clinicopathological characteristics in HBV-positive HCC patients

Clinicopathological Characteristics		VSIG4 expression		P value ^a
		Low (N=29)	High (N=35)	
Age(years)	≤45	4	4	0.776
	>45	25	31	
Gender	Male	20	19	0.231
	Female	9	16	
Child-Pugh	A	23	28	0.716
	B	4	6	
	C	2	1	
Cirrhosis	Yes	10	15	0.494
	No	19	20	
AFP (ug/L)	≤400	22	33	0.035*
	>400	7	2	
TNM stage	T ₁	15	18	0.971
	T ₂	7	10	
	T ₃	6	6	
	T ₄	1	1	
	N ₀	20	25	
	N ₁	9	10	
	M ₀	18	30	
	M ₁	11	5	
Histological grade	G1	6	5	0.744
	G2	15	21	
	G3	8	9	

a: Chi-square test, *P<0.05.

Table S4: Relationship between the VSIG4 expression and clinicopathological characteristics in HBV-negative HCC patients

Clinicopathological Characteristics		VSIG4 expression		P value ^a
		Low (N=62)	High (N=56)	
Age(years)	≤45	8	8	0.827
	>45	54	48	
Gender	Male	43	43	0.365
	Female	19	13	
Child-Pugh	A	55	48	0.877
	B	5	6	
	C	2	2	
Cirrhosis	Yes	21	24	0.316
	No	41	32	
AFP (ug/L)	≤400	46	47	0.196
	>400	16	9	
TNM stage	T ₁	38	29	0.753
	T ₂	11	14	
	T ₃	11	10	
	T ₄	2	3	
	N ₀	49	48	
N ₁	13	8		
	M ₀	48	50	0.086
	M ₁	14	6	
Histological grade	G1	8	10	0.595
	G2	34	32	
	G3	20	14	

a: Chi-square test, *P<0.05.

Table S5: Relationship between the VSIG4 expression and clinicopathological characteristics in HCC patients with HCV

Clinicopathological Characteristics		VSIG4 expression		P value ^a
		Low (N=26)	High (N=32)	
Age(years)	≤45	2	7	0.138
	>45	24	25	
Gender	Male	17	21	0.985
	Female	9	11	
Child-Pugh	A	22	26	0.909
	B	3	4	
	C	1	2	
Cirrhosis	Yes	10	13	0.867
	No	16	19	
AFP (ug/L)	≤400	23	25	0.300
	>400	3	7	
TNM stage	T ₁	20	17	0.432
	T ₂	2	5	
	T ₃	3	7	
	T ₄	1	2	
	N ₀	21	26	0.537
	N ₁	4	3	
	M ₀	20	29	0.152
	M ₁	6	3	
Histological grade	G1	3	5	0.689
	G2	13	18	
	G3	10	9	

a: Chi-square test, *P<0.05, **P<0.01.